Key result
Among 163 elderly outpatients, 20.9% had prolonged QTc and 9.2% had at-risk QTc, with no statistically significant association found between at-risk QTc and the use of QT-prolonging drugs (p=0.07).
Why the study?
Does the use of QT-prolonging drugs increase the frequency of prolonged QTc in elderly outpatients?
Cross-Sectional (n=163)
No
Does the use of QT-prolonging drugs increase the frequency of prolonged QTc in elderly outpatients?
p-value: p=0.07
A high frequency of prolonged QTc (20.9%) and at-risk QTc (9.2%) was observed in elderly outpatients, highlighting the need for ECG monitoring in this population.
OBJECTIVES: The objective of this study was to evaluate the frequency of long QT syndrome (LQTS) in the electrocardiographic tracing of elderly people and the concomitant use of drugs that can aggravate this condition. METHODS: This is a crosssectional, observational study of elderly patients in outpatient services at Hospital Santa Casa de Misericórdia de Vitória, over a six-month period. RESULTS: A total of 163 patients with 75 ± 8 (60–94) years of age, 60.7% (n = 99) of whom were female, participated in the study. Of the total number of patients, 33.1% (n = 54) were regularly taking at least one pharmaceutical that increased the risk of QTc prolongation; 34 patients (20.9%) had prolonged QTc and 15 (9,2%) had at-risk QTc. Of these patients with at-risk QTc, 4 (23.4%) were using at least 1 1 pharmaceutical that increases the risk of QT prolongation (p = 0.07). CONCLUSION: In this sample, a high frequency of LQTS was observed, as well as the use of pharmaceuticals that potentially cause LQTS and arrhythmias.
No takes yet. Share an insight, caveat, or question.
Prado et al. (2017) conducted a cross-sectional in Long QT syndrome (n=163). QT-prolonging pharmaceuticals vs. Non-use of QT-prolonging pharmaceuticals was evaluated on Frequency of at-risk QTc (≥ 500 ms) and its association with QT-prolonging drugs (p=0.07). Among 163 elderly outpatients, 20.9% had prolonged QTc and 9.2% had at-risk QTc, with no statistically significant association found between at-risk QTc and the use of QT-prolonging drugs (p=0.07).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: